Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Free Cash Flow: 2015-2024

Historic Free Cash Flow for Apellis Pharmaceuticals (APLS) over the last 10 years, with Dec 2024 value amounting to -$88.3 million.

  • Apellis Pharmaceuticals' Free Cash Flow rose 217.69% to $108.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.6 million, marking a year-over-year increase of 138.25%. This contributed to the annual value of -$88.3 million for FY2024, which is 85.18% up from last year.
  • Apellis Pharmaceuticals' Free Cash Flow amounted to -$88.3 million in FY2024, which was up 85.18% from -$595.5 million recorded in FY2023.
  • Apellis Pharmaceuticals' Free Cash Flow's 5-year high stood at -$88.3 million during FY2024, with a 5-year trough of -$595.5 million in FY2023.
  • Its 3-year average for Free Cash Flow is -$399.7 million, with a median of -$515.3 million in 2022.
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Free Cash Flow plummeted by 240.08% in 2021, and later soared by 85.18% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Free Cash Flow (Yearly) stood at -$165.9 million in 2020, then slumped by 240.08% to -$564.2 million in 2021, then grew by 8.68% to -$515.3 million in 2022, then dropped by 15.57% to -$595.5 million in 2023, then spiked by 85.18% to -$88.3 million in 2024.